MZB1的可变剪接事件是乳腺癌内分泌治疗耐药的潜在生物标志物

doi:10.11904/j.issn.1002-3070.2024.05.006

实用肿瘤学杂志 ›› 2024, Vol. 38 ›› Issue (5): 313-322.doi: 10.11904/j.issn.1002-3070.2024.05.006

MZB1的可变剪接事件是乳腺癌内分泌治疗耐药的潜在生物标志物

张宇晴¹, 荆晶², 刘兆良¹, 安静¹, 安巍巍¹

1.哈尔滨医科大学肿瘤防治研究所(哈尔滨 150081);
2.哈尔滨医科大学附属肿瘤医院放疗科

收稿日期:2024-06-27 修回日期:2024-09-23 出版日期:2024-10-28 发布日期:2025-01-09
通讯作者: 安巍巍,E-mail:601154@hrbmu.edu.cn
作者简介:张宇晴,女,(2000-),硕士研究生,从事RNA可变剪接调控与肿瘤耐药相关研究。
基金资助:
黑龙江省自然科学基金联合引导项目(编号:LH2020H111)

The alternative splicing event of MZB1 is a potential biomarker of drug resistance in endocrine therapy of breast cancer

ZHANG Yuqing¹, JING Jing², LIU Zhaoliang¹, AN Jing¹, AN Weiwei¹

1. Institute of Cancer Prevention and Treatment,Harbin Medical University,Harbin 150081,China;
2. Department of Radiology,Harbin Medical University Cancer Hospital

Received:2024-06-27 Revised:2024-09-23 Online:2024-10-28 Published:2025-01-09

摘要/Abstract

摘要： 目的利用生物信息学方法,整合基因表达谱和剪接谱,鉴定在内分泌治疗耐药中发挥作用的潜在生物标志物。方法从基因表达综合数据库(Gene expression omnibus,GEO)下载内分泌治疗敏感细胞和耐药细胞的基因数据集,筛选与内分泌治疗耐药相关的差异表达基因和差异剪接基因,并对这些基因进行Hallmark富集分析和基因集富集分析(Gene set enrichment analysis,GSEA)。下载癌症基因组图谱(The cancer genome atlas,TCGA)和乳腺癌国际联盟分子分类数据库(Molecular taxonomy of breast cancer international consortium,METABRIC)中的乳腺癌数据,比较差异基因在肿瘤组织和癌旁组织中的表达情况以及在不同肿瘤分期、分级之间的差异。探索差异基因与接受内分泌治疗患者的总生存期(Overall survival,OS)的关系及其可变剪接情况以及免疫浸润情况。结果 GEO数据分析显示,差异表达基因主要富集在乳腺癌治疗反应相关通路和免疫相关通路,差异剪接基因主要富集在乳腺癌治疗反应相关通路。同时发生差异表达和差异剪接的基因有CAMK2B、EVL、MZB1和PTPRG。其中,MZB1表达与接受内分泌治疗患者的OS以及免疫细胞浸润均相关,且在耐药细胞中MZB1的前体mRNA发生更多的可变3′端剪接。结论 MZB1表达与乳腺癌内分泌治疗疗效相关,其机制可能是通过发生可变剪接引起免疫相关功能的改变。MZB1可作为内分泌治疗改善预后的潜在生物标志物。

关键词: 乳腺癌, 内分泌治疗, 可变剪接, 免疫浸润

Abstract: Objective The aim of this study was to use bioinformatics methods to integrate gene expression profiles and splicing profiles,and identify potential biomarkers that play a role in endocrine therapy resistance. Methods The gene datasets of endocrine therapy sensitive and resistant cells from the Gene expression omnibus(GEO)database were downloaded to screen for differentially expressed genes and differential splicing genes related to endocrine therapy resistance,and perform Hallmark enrichment analysis and Gene set enrichment analysis(GSEA)on these genes.The cancer genome atlas(TCGA)and the breast cancer data in the Molecular taxonomy of breast cancer international consortium(METABRIC)were downloaded,and compared the expression of differential genes in tumor and adjacent tissues,as well as the differences between different tumor stages and grades.The relationship between differential expressed genes and overall survival(OS),alternative splicing,and immune infiltration were explored in patients receiving endocrine therapy. Results GEO data analysis showed that differentially expressed genes were mainly enriched in breast cancer treatment response related to pathways and immune-related pathways,and differentially spliced genes were mainly enriched in breast cancer treatment response related to pathways.The genes that undergo differential expression and splicing simultaneously included CAMK2B,EVL,MZB1and PTPRG.Among them,the expression of MZB1 was associated with OS and immune cell infiltration in patients receiving endocrine therapy,and the precursor mRNA of MZB1 underwent more alternative 3′splicing in drug-resistant cells. Conclusion The expression of MZB1 is related to the effect on endocrine therapy in breast cancer,and its mechanism may be the change of immune related function caused by alternative splicing.MZB1 can serve as a potential biomarker for endocrine therapy to improve prognosis.

Key words: Breast cancer, Endocrine therapy, Alternative splicing, Immune infiltration

中图分类号:

R737.9

张宇晴, 荆晶, 刘兆良, 安静, 安巍巍. MZB1的可变剪接事件是乳腺癌内分泌治疗耐药的潜在生物标志物[J]. 实用肿瘤学杂志, 2024, 38(5): 313-322.

ZHANG Yuqing, JING Jing, LIU Zhaoliang, AN Jing, AN Weiwei. The alternative splicing event of MZB1 is a potential biomarker of drug resistance in endocrine therapy of breast cancer[J]. Journal of Practical Oncology, 2024, 38(5): 313-322.

参考文献

1 Bray F,Laversanne M,Sung H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263.
2 Clusan L,Ferrière F,Flouriot G,et al.A basic review on estrogen receptor signaling pathways in breast cancer[J].Int J Mol Sci,2023,24(7):6834.
3 Will M,Liang J,Metcalfe C,et al.Therapeutic resistance to anti-oestrogen therapy in breast cancer[J].Nat Rev Cancer,2023,23(10):673-685.
4 Bradley RK,Anczuków O.RNA splicing dysregulation and the hallmarks of cancer[J].Nat Rev Cancer,2023,23(3):135-155.
5 苏文媚.RNA可变剪接在肿瘤耐药中的作用与机制[J].广东医科大学学报,2023,41(3):247-254.
6 Deng L,Liao L,Zhang YL,et al.SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1[J].Sci Adv,2024,10(14):eadj4009.
7 Yu S,Wu R,Si Y,et al.Alternative splicing of ALDOA confers tamoxifen resistance in breast cancer[J].Oncogene,2024,43(39):2901-2913.
8 Ritchie ME,Phipson B,Wu D,et al.limma powers differential expression analyses for RNA-sequencing and microarray studies[J].Nucleic Acids Res,2015,43(7):e47.
9 Quesnel-Vallières M,Jewell S,Lynch KW,et al.MAJIQlopedia:an encyclopedia of RNA splicing variations in human tissues and cancer[J].Nucleic Acids Res,2024,52(D1):D213-D221.
10 Thiebaut C,Konan HP,Guerquin MJ,et al.The role of ERα36 in development and tumor malignancy[J].Int J Mol Sci,2020,21(11):4116.
11 Belachew EB,Sewasew DT.Molecular mechanisms of endocrine resistance in estrogen-positive breast cancer[J].Front Endocrinol(Lausanne),2021,12:599586.
12 Lu C,Miao J,Li M,et al.Characterization of the estrogen response helps to predict prognosis and identify potential therapeutic targets in cholangiocarcinoma[J].Front Oncol,2022,12:870840.
13 王彤,王依琳,崔琦.上皮间质转化在乳腺癌内分泌治疗耐药中的作用研究进展[J].中国肿瘤临床,2024,51(18):961-965.
14 Hanna A,Balko JM.Breast cancer resistance mechanisms:challenges to immunotherapy[J].Breast Cancer Res Treat,2021,190(1):5-17.
15 Mirzaei S,Saghari S,Bassiri F,et al.NF-κB as a regulator of cancer metastasis and therapy response:a focus on epithelial-mesenchymal transition[J].J Cell Physiol,2022,237(7):2770-2795.
16 Zhang X,Huang L,Sun J,et al.Monopolar spindle 1 contributes to tamoxifen resistance in breast cancer through phosphorylation of estrogen receptor α[J].Breast Cancer Res Treat,2023,202(3):595-606.
17 Kim JH,Kim TW,Kim SJ.Downregulation of ARFGEF1 and CAMK2B by promoter hypermethylation in breast cancer cells[J].BMB Rep,2011,44(8):523-528.
18 Jia Q,Liao X,Zhang Y,et al.Anti-tumor role of CAMK2B in remodeling the stromal microenvironment and inhibiting proliferation in papillary renal cell carcinoma[J].Front Oncol,2022,12:740051.
19 Hu LD,Zou HF,Zhan SX,et al.EVL(Ena/VASP-like)expression is up-regulated in human breast cancer and its relative expression level is correlated with clinical stages[J].Oncol Rep,2008,19(4):1015-1020.
20 Padilla-Rodriguez M,Parker SS,Adams DG,et al.The actin cytoskeletal architecture of estrogen receptor positive breast cancer cells suppresses invasion[J].Nat Commun,2018,9(1):2980.
21 Janssens K,De Kimpe L,Balsamo M,et al.Characterization of EVL-I as a protein kinase D substrate[J].Cell Signal,2009,21(2):282-292.
22 Boni C,Sorio C.The role of the tumor suppressor gene protein tyrosine phosphatase gamma in cancer[J].Front Cell Dev Biol,2022,9:768969.
23 Shu ST,Sugimoto Y,Liu S,et al.Function and regulatory mechanisms of the candidate tumor suppressor receptor protein tyrosine phosphatase gamma(PTPRG)in breast cancer cells[J].Anticancer Res,2010,30(6):1937-1946.
24 Liu S,Sugimoto Y,Sorio C,et al.Function analysis of estrogenically regulated protein tyrosine phosphatase gamma(PTPgamma)in human breast cancer cell line MCF-7[J].Oncogene,2004,23(6):1256-1262.
25 Boni C,Laudanna C,Sorio C.A comprehensive review of receptor-type tyrosine-protein phosphatase gamma(PTPRG)role in health and non-neoplastic disease[J].Biomolecules,2022,12(1):84.
26 Watanabe M,Shibata M,Inaishi T,et al.MZB1 expression indicates poor prognosis in estrogen receptor-positive breast cancer[J].Oncol Lett,2020,20(5):198.
27 Kapoor T,Corrado M,Pearce EL,et al.MZB1 enables efficient interferon α secretion in stimulated plasmacytoid dendritic cells[J].Sci Rep,2020,10(1):21626.
28 Yuan J,Yang L,Li Z,et al.The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer[J].Front Endocrinol(Lausanne),2023,14:1261283.
29 Jing J,Zhu D,Wang X,et al.The link between aberrant splicing and B cell infiltration in breast cancer hormone therapy[J].Endocr Relat Cancer,2022,29(5):251-266.
30 Bauer MA,Ashby C,Wardell C,et al.Differential RNA splicing as a potentially important driver mechanism in multiple myeloma[J].Haematologica,2021,106(3):736-745.

[1]	庞琬莹, 安静, 刘兆良. TRIM24在乳腺癌内分泌治疗耐药中的作用及机制研究[J]. 实用肿瘤学杂志, 2024, 38(6): 402-409.
[2]	杨闽叶, 鲜童丞, 刘景建, 别俊, 王杰, 罗义. IL-23在乳腺癌组织中的表达及其与患者临床病理特征的相关性[J]. 实用肿瘤学杂志, 2024, 38(5): 323-329.
[3]	刘冬, 张太娟, 党计锋. 炎症反应驱动乳腺癌转移的研究进展[J]. 实用肿瘤学杂志, 2024, 38(5): 336-341.
[4]	李倩妮, 徐灵燕, 李健, 姚雪佩, 刘美娜. 乳腺癌多维治疗质量纵向评价的趋势分析[J]. 实用肿瘤学杂志, 2024, 38(4): 213-220.
[5]	高光强, 王发琳, 李娟, 田虹, 果思伽, 于晓兰, 杨婷婷, 刘家仁. β-紫罗兰酮通过NF-κB途径抑制乳腺癌细胞增殖[J]. 实用肿瘤学杂志, 2024, 38(4): 254-261.
[6]	邵禹铭, 朱坤兵, 张洁. SP/NK-1R系统在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(4): 268-272.
[7]	殷海燕, 淳志明, 马巧君, 成涵, 丁高恒, 张海燕, 刘玉琴. 2019年甘肃省肿瘤登记地区女性乳腺癌流行特征及2010-2019年趋势分析[J]. 实用肿瘤学杂志, 2024, 38(3): 141-148.
[8]	黑龙江省医学会乳腺肿瘤学组. 黑龙江省乳腺癌HER2低表达临床病理诊断专家共识(2024版)[J]. 实用肿瘤学杂志, 2024, 38(2): 71-78.
[9]	孟凡岗, 陈飞, 甄立军. DLX2对乳腺癌细胞增殖、迁移、侵袭、凋亡及乳腺癌干细胞特性的影响[J]. 实用肿瘤学杂志, 2024, 38(2): 88-95.
[10]	郑鹏飞, 董良鹏, 高延鑫, 张一夫, 秦双. 白细胞介素-38对乳腺癌患者CD8⁺T淋巴细胞功能的影响[J]. 实用肿瘤学杂志, 2024, 38(1): 30-36.
[11]	谢俊岭. 活化白细胞黏附分子在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(1): 45-49.
[12]	冯楚然, 曹剑钊, 陈子印, 张大昕, 鲁海玲. 乳腺癌放射性心脏损伤及其预防措施的研究进展[J]. 实用肿瘤学杂志, 2023, 37(6): 513-518.
[13]	赵诗璐, 庞达. 乳腺癌预后相关基因的生物信息学筛选与分析[J]. 实用肿瘤学杂志, 2023, 37(5): 422-428.
[14]	初思彤, 许庆勇. 三阴性乳腺癌免疫治疗耐药机制的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 449-453.
[15]	王新萍, 张自云, 王学东. 非编码RNA在乳腺癌化疗耐药中作用的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 454-458.

MZB1的可变剪接事件是乳腺癌内分泌治疗耐药的潜在生物标志物

The alternative splicing event of MZB1 is a potential biomarker of drug resistance in endocrine therapy of breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价